Keole Sameer, Ashman Jonathan B, Daniels Thomas B
From the Department of Radiation Oncology, Mayo Clinic, Phoenix, AZ.
Cancer J. 2014 Nov-Dec;20(6):409-14. doi: 10.1097/PPO.0000000000000084.
Sarcomas are a heterogeneous group of tumors that can occur in a wide array of anatomic sites and age ranges with varying histologies. Proton beam therapy, as compared with advanced x-ray radiation therapy techniques, can substantially lower dose to nontarget tissues. This dosimetric advantage can potentially allow for improvement of the therapeutic ratio in the treatment of many of the sarcomas by either increasing the local control, via increased dose to the target, or by decreasing the normal tissue complications, via lowered dose to the avoidance structures. This article reviews the key dosimetric studies and clinical outcomes published to date documenting the potential role proton beam therapy may play in the treatment of sarcomas.
肉瘤是一组异质性肿瘤,可发生于广泛的解剖部位和年龄范围,组织学类型各异。与先进的X射线放射治疗技术相比,质子束治疗可大幅降低非靶组织的剂量。这种剂量学优势有可能通过增加靶区剂量提高局部控制率,或通过降低避让结构的剂量减少正常组织并发症,从而提高许多肉瘤治疗的治疗比。本文综述了迄今为止发表的关键剂量学研究和临床结果,记录了质子束治疗在肉瘤治疗中可能发挥的潜在作用。